Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma Life Science Investing
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 Life Science Investing
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates Life Science Investing
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update Life Science Investing
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results Life Science Investing
One Additional Inch of Rainfall from Ground-Based Rain Enhancement Worth $44 Million Annually to 37 Texas Counties, Texas A&M Analysis Finds Life Science Investing
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update Life Science Investing
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides Life Science Investing
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow Life Science Investing
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights Life Science Investing
